Long-term experience with treatment of AMD with use of ranibizumab – clinical examples
Article Sidebar
Published:
Jun 30, 2014
Keywords:
AMD, anti-VEGF treatment, ranibizumab
Main Article Content
Abstract
Years of trials of treating the wet form of AMD resulted in the development and introduction into clinical practice the VEGF-blocking drugs. Among the drugs currently available ranibizumab which is used for eight years now has the strongest evidence of its efficacy and safety, proved by large number of clinical studies. In our material of several thousand injections we have observed minimum number of adverse drug reactions and no serious adverse drug reactions. We are aiming to present the clinical examples of patients with neovascular AMD treated effectively with the injections of intravitreal ranibizumab in the long term of observation. Ranibizumab is currently used by us successfully not only in exudative AMD but also in four other treatment indications: BRVO, CRVO, DME and mCNV.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Wykrota H, Trzciąkowski K. Long-term experience with treatment of AMD with use of ranibizumab – clinical examples. Ophthatherapy [Internet]. 2014Jun.30 [cited 2024Jul.3];1(2):76-3. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/674
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997; 115(6): 741-7.
2. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994; 112(4): 480-8.
3. Bressler N. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials – tap report 2. Arch Ophtalmol. 2001; 119(2): 198-207.
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin Therapy for Subfoveal Choroidal Neowascularization in Age-Related Macular degeneration. Arch Ophthalmol. 2002; 120: 1307-14.
5. Tatar O., Adam A., Shinoda K. et al.: Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006; 142(1): 95-104.
6. Ferrara N, Gerber H, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003; 99(6): 669-76.
7. Gragoudas E, Adamis A, Cunningham E et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27): 2805-16.
8. Avery R, Pieramici D, Rabena M et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113 (3): 363-72.
9. Rosenfeld P, Brown D, Heier J et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419-31.
10. Larsen M, Schmidt-Erfurth U, Lanzetta P et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology. 2012; 119(5): 992-1000.
11. Holz G, Amoaku W, Donate J et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology. 2011; 118(4): 663-71.
12. Chakravarthy U, Harding S, Rogers C et al; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 9900(382): 1258-67.
13. Kaiser P, Boyer D, Cruess A et al; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012; 119(5): 1001-10.
14. Busbee B, Ho A, Brown D et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120(5): 1046-56.
15. Mitchell P, Korobelnik J, Lanzetta P et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010; 94(1): 2-13.
16. Ying G, Kim B, Maguire M et al; for the CATT Research Group. Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. 2014 May 29. https://doi.org/10.1001/jamaophthalmol.2014.1019.
17. Fung A, Lalwani G, Rosenfeld P et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566-83.
18. Lalwani G, Rosenfeld P, Fung A et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43-58.
19. Jackson T, Dugel P, Bebchuk J et al.; CABERNET Study Group. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology. 2013; 120(8): 1597-603.
20. Schmidt-Erfurth U, Kaiser P, Korobelnik J et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014; 121(1): 193-201.
21. Holz F, Bandello F, Gillies M et al; on behalf of the LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme Br J Ophthalmol. 2013; 97(9): 1161-7.
22. Lucentis (ranibizumab). Charakterystyka produktu leczniczego. 05.2014.
2. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994; 112(4): 480-8.
3. Bressler N. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials – tap report 2. Arch Ophtalmol. 2001; 119(2): 198-207.
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin Therapy for Subfoveal Choroidal Neowascularization in Age-Related Macular degeneration. Arch Ophthalmol. 2002; 120: 1307-14.
5. Tatar O., Adam A., Shinoda K. et al.: Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006; 142(1): 95-104.
6. Ferrara N, Gerber H, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003; 99(6): 669-76.
7. Gragoudas E, Adamis A, Cunningham E et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27): 2805-16.
8. Avery R, Pieramici D, Rabena M et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113 (3): 363-72.
9. Rosenfeld P, Brown D, Heier J et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419-31.
10. Larsen M, Schmidt-Erfurth U, Lanzetta P et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology. 2012; 119(5): 992-1000.
11. Holz G, Amoaku W, Donate J et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology. 2011; 118(4): 663-71.
12. Chakravarthy U, Harding S, Rogers C et al; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 9900(382): 1258-67.
13. Kaiser P, Boyer D, Cruess A et al; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012; 119(5): 1001-10.
14. Busbee B, Ho A, Brown D et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120(5): 1046-56.
15. Mitchell P, Korobelnik J, Lanzetta P et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010; 94(1): 2-13.
16. Ying G, Kim B, Maguire M et al; for the CATT Research Group. Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. 2014 May 29. https://doi.org/10.1001/jamaophthalmol.2014.1019.
17. Fung A, Lalwani G, Rosenfeld P et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566-83.
18. Lalwani G, Rosenfeld P, Fung A et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43-58.
19. Jackson T, Dugel P, Bebchuk J et al.; CABERNET Study Group. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology. 2013; 120(8): 1597-603.
20. Schmidt-Erfurth U, Kaiser P, Korobelnik J et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014; 121(1): 193-201.
21. Holz F, Bandello F, Gillies M et al; on behalf of the LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme Br J Ophthalmol. 2013; 97(9): 1161-7.
22. Lucentis (ranibizumab). Charakterystyka produktu leczniczego. 05.2014.